Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.

Research Base: Alliance for Clinical Trials in Oncology
NCT ID: NCT03087708
NCI Protocol Number: A221504
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Naloxegol; Placebo; Laboratory Biomarker Analysis; Quality-of-Life Assessment

Condition

Stage IIIB Lung Adenocarcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP